AbbVie grows oncology pipeline with Stemcentrx acquisition
NORTH CHICAGO — Biopharmaceutical company AbbVie on Thursday announced its planned acquisition of Stemcentrx and its late-stage potential treatment for small cell lung cancer, Rova-T (rovalpituzumab tesirine).
“AbbVie is committed to continued innovation in oncology, a critical component of our long-term growth and an area of significant need to millions of patients worldwide,” AbbVie chairman and CEO Richard Gonzalez said. “The addition of Stemcentrx and its late-stage compound Rova-T provide AbbVie with a unique platform in solid tumor therapeutics and complement our leadership position in hematologic oncology. We believe the acquisition of Stemcentrx will strengthen and accelerate our ability to deliver innovative therapies that will have a remarkable impact on patients' lives.”
Rova-T is under investigation as a potential third-line treatment for SCLC, for which there isn’t an approved therapy and it has been submitted to the Food and Drug Administration for consideration for Breakthrough Therapy designation.
“We are thrilled to be joining the AbbVie team and believe that, together, we can bring much-needed therapies to cancer patients," Stemcentrx founder and CEO Brian Slingerland said. “AbbVie, with its long-term commitment and expertise in drug development, will help us turn our scientific discoveries into a mainstay of cancer treatments."
iMedicare reports saving patients $287.5 million in 2015
NEW YORK — Medicare plan comparison platform iMedicare on Thursday announced that in 2-15 it helped more than 250,000 patients save an average of $1,150 on their expected Medicare Part D costs — a collective savings of $287.5 million.
iMedicare’s platform allows pharmacies to easily compare Medicare plan options for patients based on their medication needs, costs and plan service area.
“Around 80% of Medicare patients can save money each year by finding a more affordable Medicare plan. We are excited that our pharmacies went above and beyond to identify these patients and deliver such immense savings,” says Nathan Shanor, CFO of iMedicare. “As the Medicare population continues to grow, we look forward to iMedicare pharmacies yielding even greater results.”
Emergency delivery of lifesaving medicine inspires ABC fundraiser supporting rare disorder research
CONSHOHOCKEN, Pa. – The AmerisourceBergen Foundation and AmerisourceBergen associates on Thursday announced two donations totaling $32,000 to support rare disorder research. The donations were awarded to the Canadian Organization for Rare Disorders and the National Organization for Rare Disorders, two non-profit organizations devoted to identifying and treating rare disorders through patient services and education, advocacy and research programs.
The donations were inspired by a 13-hour, nearly 600-mile overnight truck delivery to provide lifesaving treatment to a newborn at a Toronto hospital on Christmas Day. On Dec. 23, 2015, ICS, a part of AmerisourceBergen, received a request to ship a specific medication to the hospital for a baby suffering from a rare condition that, if left untreated, could result in death. The prescribed medication is not traditionally available in Canada, so upon receiving the approval from Health Canada at mid-afternoon on Christmas Eve, the ICS team reopened its distribution center to process the order.
With no flights available, a team of ICS, World Courier and Innomar Strategies associates developed a plan to deliver the treatment within the tight timeframe. The plan, which included multiple drivers and several shipment handoffs, kicked off at 7:35 p.m. in Louisville, Ky. After receiving clearance at the Canadian border at 4:11 a.m., the final World Courier driver loaded the shipment and reached the hospital at 8:35 a.m., ultimately delivering the medication in time to save the baby’s life.
“Our associates’ commitment to overcoming obstacles and delivering the life-saving treatment in time underscores our patient-centered approach to healthcare,” said Doug Cook, president of Global Specialty Logistics at AmerisourceBergen. “We recognize that certain situations require unique solutions, and we’re able to leverage our resources and expertise to ensure patients receive the medication they need, when they need it.”
“Every day, we work to shape health care delivery, so we’re proud of how both our associates and the AmerisourceBergen Foundation responded to this lifesaving delivery and rallied to further support rare disorder research,” said Esperanza Neu, executive director of the AmerisourceBergen Foundation and VP workplace services, diversity and community relations at AmerisourceBergen. “We’re grateful that we can support leading non-profits as they pursue their mission to promote research, diagnosis and treatment for rare disorders.”
AmerisourceBergen has previously worked with CORD and NORD to further support rare disease research. Innomar Strategies, the leading Canadian service provider for specialty pharmaceuticals and a part of AmerisourceBergen, partners with CORD to bring awareness to rare disorders through a variety of events, including interactive seminars.
Loading Post Please Wait...